Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Freiburg ZNS-NHL Study

Phase 2

Conditions: Primary Non Hodgkin Lymphoma of the Central Nervous System

Interventions: Drug: methotrexate
Drug: Rituximab
Drug: Cytarabine
Drug: Thiotepa
Drug: Carmustin

First Posted Date: 2008-03-31

Last Posted Date: 2009-11-17

Lead Sponsor: University Hospital Freiburg

Target Recruit Count: 78

Registration Number: NCT00647049

Locations: 🇩🇪
University Hospital Freiburg, Freiburg, Germany

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: mitoxantrone hydrochloride
Drug: carboplatin
Drug: alvocidib
Drug: topotecan hydrochloride
Drug: cytarabine
Drug: sirolimus
Drug: etoposide

First Posted Date: 2008-03-12

Last Posted Date: 2015-07-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT00634244

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 17 locations

BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: BI 811283 (d 1 and 15)
Drug: BI 811283 (d1)
Drug: Cytarabine

First Posted Date: 2008-03-11

Last Posted Date: 2015-09-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT00632749

Locations: 🇩🇪
1247.3.49004 Boehringer Ingelheim Investigational Site, Freiburg, Germany
🇩🇪
1247.3.49007 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪
1247.3.49005 Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany

and more 4 locations

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Phase 2

Terminated

Conditions: Peripheral T-Cell Lymphoma

Interventions: Drug: Gemcitabine
Drug: Navelbine
Drug: Doxorubicin Hydrochloride Liposome Injection
Drug: Granulocyte-colony stimulating factor (G-CSF)
Drug: Pegfilgrastim
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Leucovorin
Drug: Methotrexate
Drug: Doxorubicin Hydrochloride
Drug: Cytarabine
Drug: Etoposide
Drug: Carmustine
Drug: Denileukin diftitox

First Posted Date: 2008-03-11

Last Posted Date: 2020-04-27

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 21

Registration Number: NCT00632827

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States

A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: LY2181308 sodium
Drug: cytarabine
Drug: idarubicin

First Posted Date: 2008-02-21

Last Posted Date: 2019-09-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT00620321

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States

Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2008-02-20

Last Posted Date: 2013-03-26

Lead Sponsor: Asan Medical Center

Target Recruit Count: 50

Registration Number: NCT00618501

Locations: 🇰🇷
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: Asparaginase
Drug: dexamethasone
Drug: Etoposide
Drug: cyclophosphamide
Drug: Ifosfamide
Drug: cytarabine
Drug: daunorubicin
Drug: doxorubicin
Drug: mercaptopurine
Drug: Vindesine
Drug: Methotrexate
Drug: prednisone
Drug: thioguanine
Drug: Vincristine

First Posted Date: 2008-02-13

Last Posted Date: 2015-01-14

Lead Sponsor: Associazione Italiana Ematologia Oncologia Pediatrica

Target Recruit Count: 2039

Registration Number: NCT00613457

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

Phase 1

Terminated

Conditions: Leukemia

Interventions: Drug: cyclosporine
Drug: cytarabine
Drug: filgrastim
Drug: methotrexate
Drug: methylprednisolone
Drug: mitoxantrone hydrochloride
Procedure: allogeneic bone marrow transplantation
Procedure: umbilical cord blood transplantation
Drug: Cis-Retinoic acid

First Posted Date: 2008-02-07

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 1

Registration Number: NCT00609739

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Promyelocytic Leukemia (M3)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia